99% Manufacturer For Sale anti-hairloss Setipiprant Powder Online
What is Setipiprant?
Setipiprant is a drug orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma.
However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness,[5] the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action.
A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.
Setipiprant Powder Basic Information
| Product Name |
Setipiprant
|
| Synonym |
2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid;Setipiprant;ACT129968;2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid;ACT-129968 (Setipiprant);8-Fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-5H-pyrido[4,3-b]indole-5-acetic acid;2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid;2-(2-(1-phthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid |
| CAS |
866460-33-5 |
| MF |
C24H19FN2O3 |
| MW |
402.4176632 |
| Appearance |
Pale Yellow Powder |
| Grade |
Pharma Grade |
| Usage |
Anti-Hair Loss |
| MOQ |
10g |
Setipiprant certificate of Analysis
| Product name |
Setipiprant |
| CAS No. |
866460-33-5 |
Outer Packing |
1kg/bag |
| Production date |
18th Jan 2018 |
Shelf life |
17th Jan 2020 |
| Standard adopted |
Enterprise Standard |
| Items of analysis |
Specification |
Results |
| Appearance |
White to light yellow powder |
White powder |
| Identification |
Positive |
Conforms |
| Purity |
98%+ |
99.25% |
| Conclusion |
Qualified |
